A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

Depression and Anxiety

Volumn 23, Issue 6, 2006, Pages 364-372

  Corya, Sara A ^a   Williamson, Doug ^a   Sanger, Todd M ^a   Briggs, Susan D ^a   Case, Michael ^a   Tollefson, Gary ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressive agents; Antipsychotic agents; Depressive disorder; Drug combinations; Serotonin uptake inhibitors

Indexed keywords

CITALOPRAM; FLUOXETINE; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OPEN STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

BENZODIAZEPINES; BRIEF PSYCHIATRIC RATING SCALE; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT REFUSAL;

EID: 33750374140     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20130     Document Type: Article

References (31)

1. Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
2. Cadieux RJ. 1998. Practical management of treatment-resistant depression. Am Fam Physician 58:2059-2062.
3. Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ. 2002. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry 63:717-726.
4. Corya SA, Andersen SW, Detke HC, Kelly LS, Van Campen LE, Sanger TM, Williamson DJ, Dube S. 2003. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: A 76-week open-label study. J Clin Psychiatry 64:1349-1356.
5. De Montigny C, Silverstone PH, Debonnel G, Blier P, Bakish D. 1999. Venlafaxine in treatment-resistant major depression: A Canadian multicenter, open-label trial. J Clin Psychopharmacol 19:401-406.
6. Dubé S, Corya SA, Andersen SW, Detke HC, Blansette S, Tollefson GD. 2002. Efficacy of olanzapine/fluoxetine combination in treatment-resistant depression. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology; December 9, 2002; San Juan, Puerto Rico.
7. Fava M, Davidson KG. 1996. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19: 179-200.
8. Frank E, Kupfer DJ. 1990. Axis II personality disorders and personality features in treatment-resistant and refractory depression. In: Roose SP, Glassman AH, editors. Treatment strategies for refractory depression. Washington, DC: American Psychiatry Press. p 205-221.
9. Georgotas A, McCue RE, Cooper TB, Nagachandran N, Friedhoff A. 1989. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res 28:1-9.
10. Greenhouse JB, Kupfer DJ, Frank E, Jarrett DB, Rejman KA. 1987. Analysis of time to stabilization in the treatment of depression: Biological and clinical correlates. J Affect Disord 13:259-266.
11. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
12. Kaplan EM. 2002. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: An open-label, uncontrolled study. Clin Ther 24:1194-1200.
13. Kennedy SH, Lam RW. 2003. Enhancing outcomes in the management of treatment resistant depression: A focus on atypical antipsychotics. Bipolar Disord 5(Suppl. 2):36-47.
14. Klerman GL. 1987. Clinical epidemiology of suicide. J Clin Psychiatry 48(Suppl):33-38.
15. Mallinckrodt CH, Clark WS, David SR. 2001. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 11: 9-21.
16. Montgomery SA, Åsberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
17. Murray CJ, Lopez AD. 1996. The global burden of disease: A comprehensive assessment of mortality and disability from disease, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press.
18. National Institute of Mental Health. 1976a. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville, MD: U.S. National Institute of Health. p 534-537.
19. National Institute of Mental Health. 1976b. Clinical global impressions (CGI). In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville, MD: U.S. National Institute of Health. p 217-222.
20. Nierenberg AA, Amsterdam JD. 1990. Treatment-resistant depression: Definition and treatment approaches. J Clin Psychiatry 51(Suppl):39-47.
21. Overall JE, Gorham DR. 1962. The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
22. Poirier MF, Boyer P. 1999. Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison. Br J Psychiatry 175:12-16.
23. Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M, Rosenbaum J, Reimherr F, Fawcett J, Chen Y, Klein D. 2003. When should a trial of fluoxerine for major depression be declared failed? Am J Psychiatry 160:734-740.
24. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD. 2004. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 24:365-373.
25. Rudolph RL, Derivan AT. 1996. The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database. J Clin Psychopharmacol 16:54S-59S.
26. Russell JM, Hawkins K, Ozminkowski RJ, Orsini L, Crown WH, Kennedy S, Finkelstein S, Berndt E, Rush AJ. 2004. The cost consequences of treatment-resistant depression. J Clin Psychiatry 65:341-347.
27. Schweitzer I, Burrows G, Tuckwell V, Polonowita A, Flynn P, George T, Theodoros M, Mitchell P. 2001. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol 21:185-189.
28. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. 2001. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131-134.
29. Simpson GM, Angus JWS. 1970. A raring scale for extrapyramidal side effects. Acta Psychiatr Scand 212(Suppl):11-19.
30. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. 2003. Efficacy of olanzapine and olanzapine-fluoxerine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079-1088.
31. Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP. 2000. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxerine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23:250-262.